We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 8,128

Monsanto Asserts no Government role in determining the Licensing Fee
  • RNA IP Attorneys
  • India
  • April 26 2017

The tug of war between Monsanto and its erstwhile licensees over licensing fee and Patent infringement continues unabated. The

Changes to Pharmaceutical Extension of Term application procedures the latest front in the battle for savings in Australia’s healthcare budget
  • Watermark Patent & Trade Marks Attorneys
  • Australia
  • April 26 2017

It’s no secret that the Australian Government is struggling to manage the cost of its healthcare obligations. Increasingly it seems these struggles

Gut check: microbiome patent update
  • Nixon Peabody LLP
  • USA
  • April 26 2017

Despite challenges imposed by U.S. patent law regarding naturally-occurring organisms and their products, patents relating to the microbiome and

Federal Circuit reverses district court holding in generics case
  • Baker Donelson Bearman Caldwell & Berkowitz PC
  • USA
  • April 26 2017

The Federal Circuit has reversed a decision that Mylan Inc's proposed generic version of a drug infringed one of two patents owned by the Medicines

UV Curable Coatings: No Exergen, but PTAB Decision Leads to Stricken Inequitable Conduct Defense
  • Morrison & Foerster LLP
  • USA
  • April 25 2017

In a recent decision in UV Curable Coatings for Optical Fibers, Inv. No. 337-TA-1031, Judge MaryJoan McNamara struck a respondent’s inequitable

How Soon Can A Biosimilar Applicant Be Sued for Patent Infringement?
  • Fish & Richardson PC
  • USA
  • April 24 2017

Biosimilar manufacturers proceeding under the abbreviated approval pathway laid out in the Biologics Price Competition and Innovation Act ("BPCIA"

Novartis’ Gilenya Patent Invalidated as Obvious
  • Knobbe Martens Olson & Bear LLP
  • USA
  • April 24 2017

On April 12, 2017, the Federal Circuit affirmed the determination by the US Patent and Trademark Office (USPTO), Patent Trial and Appeal Board (Board

Improved IP-situation in Brazil for pharmaceutical patent applications
  • Valea AB
  • Brazil
  • April 21 2017

Last week, the President of Brazil, Michel Temer, revealed measures aimed at improving the IP-system in the country. One measure is to employ more

Just How Predictable Must the Invention Be to Lose Patent Protection? Depends on the Inventive Concept
  • Bennett Jones LLP
  • Canada
  • April 21 2017

Only a true invention can be patented; a patent claim to an invention is not valid if the invention was obvious. Assessing obviousness can be thought

Protective Agreements Before and During BPCIA Litigation: Prosecution and Regulatory Bars
  • Fish & Richardson PC
  • USA
  • April 20 2017

Protective orders that regulate the disclosure and use of confidential information exchanged during patent litigations are commonplace. However, the